During the past decade, Moffitt Cancer Center conducted 913 clinical trials. In the 10-year time frame, 913 clinical trials started and 438 clinical trials were completed, i.e. on average, 48% percent of trials that started reached the finish line to date. In the past 5 years, 423 clinical trials started and 255 clinical trials were completed. i.e. 60.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Moffitt Cancer Center" #1 sponsor was "H. Lee Moffitt Cancer Center and Research Institute" with 419 trials, followed by "National Cancer Institute (NCI)" with 159 trials sponsored, "Bristol-Myers Squibb" with 47 trials sponsored, "Radiation Therapy Oncology Group" with 40 trials sponsored and "Gynecologic Oncology Group" with 40 trials sponsored. Other sponsors include 988 different institutions and companies that sponsored additional 414 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Moffitt Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 328 trials as a collaborator, "Bristol-Myers Squibb" with 42 trials as a collaborator, "Merck Sharp & Dohme LLC" with 42 trials as a collaborator, "H. Lee Moffitt Cancer Center and Research Institute" with 32 trials as a collaborator and "Blood and Marrow Transplant Clinical Trials Network" with 30 trials as a collaborator. Other collaborators include 843 different institutions and companies that were collaborators in the rest 357 trials.

According to Clinical.Site data, the most researched conditions in "Moffitt Cancer Center" are "Breast Cancer" (79 trials), "Multiple Myeloma" (72 trials), "Melanoma" (61 trials), "Ovarian Cancer" (54 trials) and "Prostate Cancer" (50 trials). Many other conditions were trialed in "Moffitt Cancer Center" in a lesser frequency.

Most popular intervention types in "Moffitt Cancer Center" are "Drug" (1303 trials), "Biological" (328 trials), "Other" (252 trials), "Procedure" (199 trials) and "Radiation" (165 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (88 trials), "Laboratory Biomarker Analysis" (86 trials), "Placebo" (72 trials), "Pembrolizumab" (58 trials) and "Cyclophosphamide" (52 trials). Other intervention names were less common.

The vast majority of trials in "Moffitt Cancer Center" are 1486 trials for "All" genders, 146 trials for "Female" genders and 64 trials for "Male" genders.

Currently, there are NaN active trials in "Moffitt Cancer Center". 4 are not yet recruiting, 311 are recruiting, 299 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 800 completed trials in Moffitt Cancer Center, 12 suspended trials, and 214 terminated clinical trials to date.

Out of the total trials that were conducted in Moffitt Cancer Center, 538 "Phase 1" clinical trials were conducted, 846 "Phase 2" clinical trials and 287 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 134 trials that are defined as “Not Applicable".

Moffitt Cancer Center has several departments that took part in Clinical trials: "Moffitt Cancer Center - McKinley Campus" - 49 trials, "Moffitt Cancer Center-International Plaza" - 48 trials, "Moffitt Cancer Center - Magnolia Campus" - 2 trials